Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System

Phase 1

Recruiting

• Conditions: Prostate Cancer
• Interventions: Device: Photodynamic Therapy (PDT); Drug: Verteporfin Injection

• Registration Number: NCT06807359
• Lead Sponsor: SpectraCure AB

Brief Summary

The goal of this study is to obtain safety data, establish dose parameters, and effectiveness of treatment for the SpectraCure P18 System with IDOSE®, together with verteporfin for injection (VFI) as photosensitizer, for the treatment of primary localized prostate cancer.

The study will be divided into two parts, with Phase I, dose-escalation, to study safety and establish an effective light dose, followed by Phase II, cohort expansion, to evaluate clinical efficacy and confirm safety/tolerability. The subjects will be followed for a period of 18 months to determine the primary outcome. The long-term follow-up is an additional 18 months, i.e. a total of 36 months.

Interstitial Photodynamic Therapy (PDT) will be performed during general anesthesia. Optical fibers will be inserted into the prostate with a transperineal approach using transrectal ultrasound guidance. The intent is to deliver an adequate light dose throughout the prostate. Subjects will receive VFI intravenously, approximately 60-90 minutes prior to light delivery.

Detailed Description

Not available

Study Timeline

• Study Start: 2025-01-06
• Study First Submitted: 2025-01-29
• Study First Submitted QC: 2025-01-29
• Status Verified: 2025-02
• Study First Posted: 2025-02-04
• Last Update Submitted: 2025-02-04
• Last Update Posted: 2025-02-07
• Primary Completion: 2028-01
• Study Completion: 2029-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Male
• Target Recruitment: 43

Inclusion Criteria

1. Subjects ≥ 18 years.

2. Histologically confirmed organ-confined adenocarcinoma of the prostate cancer diagnosed within the last 9 months. Including subjects on active surveillance with evidence of disease progression and a prostate biopsy not older than 9 months.

   a. This prostate biopsy should be targeted and systematic (transperineal or transrectal are both acceptable) and include both systematic sampling with a minimum of 8 cores (4 right, 4 left) as well as MRI fusion targeted cores. The minimum number of targeted cores is two (2) but more may be included at the discretion of the surgeon.

3. Gleason Score 7 (3+4 or 4+3).

4. PSA ≤ 15 ng/mL.

5. Lesion volume on mpMRI < 1.5 cm3.

6. Adequate stage imaging such as pelvic CT/MRI/PET scan within the last 6 months confirming localized cancer.

   • Bone scan is optional if PSA < 10 ng/mL.

7. Treatment target volume <50 cm3 defined by TRUS or MRI.

8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

9. Expected survival ≥ 36 months.

10. Sufficient bone marrow reserve as indicated by; granulocyte count ≥ 1500/mm3, platelet count ≥ 100,000/mm3.

11. Adequate renal function as defined by creatinine ≤ 1.5 mg /dl.

12. Adequate hepatic function, based on a total bilirubin ≤ 1.5 mg/dl, serum glutamate-oxaloacetate transaminase (SGOT) ≤ 3 times the upper limit of normal, and alanine transaminase (ALT) ≤ 3 times the upper limit of normal.

13. Signed Informed Consent.

Exclusion Criteria

1. Evidence of locally advanced, regional pelvic lymph node metastasis, or metastatic disease.

2. Any suspicious for, probable, or definite extracapsular extension on pretreatment MRI

3. Contralateral PIRADS 4/5 lesion (even if negative targeted biopsy)

4. High volume GG1 disease in the contralateral prostate, outside of the ablation zone. High volume is defined as >1 core of GG1 with a linear amount of carcinoma >6mm.

5. Prior radical surgery for carcinoma of the prostate, prior pelvic radiation, prior TURP, prior cryosurgery of the prostate.

6. Prior treatment with any form of brachytherapy.

7. Previous androgen deprivation therapy (ADT) or chemotherapy for prostate cancer.

8. Prior or current bleeding diathesis.

9. Tumors known to be eroding into a major blood vessel in or adjacent to the illumination site.

10. Use of Alpha-reductase inhibitors (ARIs) within 90 days of enrolment.

11. Any serious active or co-morbid medical conditions, laboratory abnormality, psychiatric illness, active or uncontrolled infections, or serious illnesses or medical conditions that would prevent the patient from participating or to be managed according to the protocol (according to investigator's decision).

12. Mental incapacity or psychiatric illness that would interfere with the subject's ability to understand and give informed consent or to complete follow-up visits according to the judgement of the investigator.

13. Contraindication for photosensitizer including:

    1. Porphyria or other diseases exacerbated by light.
    2. Known hypersensitivity to verteporfin for injection (VFI) or to any of the excipients.
    3. Known allergies to porphyrins.

14. On-going therapy with a photosensitizing agent.

15. Enrolment in another therapeutic clinical study within 3 month prior to enrolment and throughout the study.

16. Contraindication for MRI/Gadolinium contrast such as: implants, hip prosthesis, severe renal impairment (glomerular filtration rate [GFR] <30 mL/min/1.73m2), or previous contrast reactions.

17. Has known hypersensitivity to pancuronium bromide, atricurium or cisatricurium

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
PDT with VFI	Photodynamic Therapy (PDT)	Interstitial Photodynamic Therapy (PDT) and Verteporfin for Injection (VFI)
PDT with VFI	Verteporfin Injection	Interstitial Photodynamic Therapy (PDT) and Verteporfin for Injection (VFI)

Primary Outcome Measures

Name	Time	Method
Safety of treatment	Within 4 weeks of treatment in each cohort.	Number of participants with treatment related adverse events as assessed by CTCAE v5.0 related to therapy per protocol.; Dose limiting toxicities are defined as grade 3 non-hematologic or grade 4 hematologic toxicities that are possibly, probably or definitely related to PDT.
Safety - Damage to the periprostatic tissue mediated by PDT	5-9 days following PDT	Potential damage to the periprostatic tissue will be evaluated by contrast-enhanced and not-contrast enhanced MRI.
Treatment efficacy	6 and 18 months post PDT	Percentage of subjects with negative in-field biopsies (histopathologically tumor-free)

Secondary Outcome Measures

Name	Time	Method
Adequacy of effectiveness	Within 1 week following PDT	Extent of quantifiable treatment effect in the prostate evaluated by MRI to determine the extent of necrosis in the prostate
Treatment efficacy	6 and 18 months post PDT	Rate of negative in-field biopsy as defined by the Delphi consensus criterion (≤ 3 mm of Gleason ≤ 6 disease in any biopsy core is insignificant).
Device performance	Day of PDT	Light dose coverage \>90% of the target volume; evaluated by dose-volume histograms in \>80% of subjects
Percentage of subjects with biochemical failure	6 and 10 weeks, 6, 18, 24 and 36 months post PDT	Failure defined as a rise in PSA level of 2.0 ng/mL or more, over and above the nadir
Percentage of subjects with extra prostatic or distant disease	6 and 18 months post PDT	Remaining localized tumour will be evaluated by MRI

Trial Locations

Locations (1)

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States